Top Story

MPDL3280A shows promise in metastatic triple-negative breast cancer

April 20, 2015

Read the Perspective from Louis M. Weiner, MD

PHILADELPHIA — The investigational immunotherapy MPDL3280A appeared well tolerated and demonstrated favorable efficacy in patients with metastatic triple-negative breast cancer, according to study results presented at the American Association for Cancer Research Annual Meeting.

“Triple-negative breast cancer tends to have a higher mutation rate than other breast cancer subtypes,” Leisha A. Emens, MD, PhD, associate professor of oncology and member of the cancer immunology and breast/ovarian cancer programs at Johns Hopkins Kimmel Cancer Center, said during a press conference. “This lends to its ability to produce neoantigens, which can be recognized as foreign by the immune system and can be more effective targets for the immune response than other antigens.”

Stephen F Hodi Meeting News CoveragePerspective

Simultaneous treatment with ipilimumab, nivolumab improves outcomes in advanced melanoma

April 20, 2015
PHILADELPHIA — Patients with treatment-naive advanced melanoma who underwent simultaneous treatment with ipilimumab and nivolumab demonstrated longer PFS and a…

Yale launches personalized therapy trial for metastatic melanoma

April 20, 2015
Yale University announced recently that it has begun a multicenter clinical trial to apply personalized medicine technology to the treatment of metastatic melanoma.The…
Jedd Wolchok Meeting News Coverage

ACS, Stand Up To Cancer announce lung cancer research initiative

April 20, 2015
PHILADELPHIA — Stand Up to Cancer, or SU2C, and the American Cancer Society today announced the formation of a $20 million lung cancer “Dream Team”…
FDA News

FDA, SillaJen agree to begin phase 3 liver cancer trial

April 20, 2015
SillaJen, Inc. has reached an agreement with the FDA on a Special Protocol Assessment for a phase 3 clinical trial of its drug Pexa-Vec for the treatment of advanced…
More News Headlines »
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

April 12, 2015
Robert O. Dillman, MD, vice president of oncology at NeoStem Inc., provides an overview of a phase 3 trial evaluating…
More »
Hematology Oncology Case Consults

Diagnosis and Management of Hemophilia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of the patient with hemophilia supplemented with a case…
More »